288
Views
8
CrossRef citations to date
0
Altmetric
Articles

Synthesis, characterization, and antitumour studies of some curcuminoid analogues and their aluminum complexes

, &
Pages 1508-1518 | Received 02 Oct 2012, Accepted 23 Jan 2013, Published online: 19 Apr 2013
 

Abstract

Aluminum(III) complexes of three curcuminoid analogues [1,7-diphenyl-1,6-heptadiene-3,5-dione, HL1; 1,7-bis(2-hydroxyphenyl)-1,6-heptadiene-3,5-dione, HL2; and 1,7-bis(4-ethoxyphenyl)-1,6-heptadiene-3,5-dione, HL3] of [AlL3] stoichiometry were synthesized and characterized by UV, IR, 1H NMR, and mass spectral data. The compounds were investigated for cytotoxic and antitumor activities. The aluminum chelates are remarkably active compared to free curcuminoid analogues. The aluminum complex of HL2 with hydroxyl in the phenyl ring was most active towards Ehrlich ascites carcinoma cells (concentration needed for 50% inhibition of 5 μg/mL) and cultured L929 cells (1 μg/mL produced 60 + 3% cell death). Increase in lifespan and reduction of solid tumor volume in mice were also largest for the aluminum complex of HL2. The study reveals that the antitumor activities of curcuminoids are more enhanced by complexation with aluminum than with transition metal ions.

Acknowledgments

The authors are grateful to Dr Girija Kuttan and the Director of the Amala Cancer Research Centre, Thrissur, Kerala, India, for their help in the antitumor studies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.